[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659944":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":13,"studyPopulation":13,"armGroups":45,"interventions":56,"overallOfficials":64,"centralContacts":68,"locations":74,"responsibleParty":90,"collaborators":93,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":13,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":105,"minAge":106,"maxAge":13,"enrollmentInfo":107,"targetDuration":13,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":13,"overallStatus":118,"whyStopped":13,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"University of Colorado, Boulder","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":14},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in endothelial function at 3 months","Brachial artery flow-mediated dilation","3 months",null,[15,18,21,24,27,29,32],{"measure":16,"description":17,"timeFrame":12},"Change from baseline in suppression of endothelial function by mitochondrial oxidative stress at 3 months","Change in brachial artery flow-mediated dilation with acute, supratherapeutic MitoQ (160mg)",{"measure":19,"description":20,"timeFrame":12},"Change from baseline in the effects of circulating factors on endothelial cell nitric oxide (NO) and total and mitochondrial reactive oxygen species (mitoROS) production at 3 months","Effects of changes circulating factors on endothelial cell nitric oxide (NO) and total and mitochondrial reactive oxygen species (mitoROS) production using human aortic endothelial cells in culture",{"measure":22,"description":23,"timeFrame":12},"Change from baseline in cerebrovascular function at 3 months","Change in middle cerebral artery reactivity and\u002For internal carotid artery \\[ICA\\] dilation to hypercapnia, and\u002For MCA pulsatility index, and\u002For total cerebral blood flow at 3 months",{"measure":25,"description":26,"timeFrame":12},"Change from baseline in endothelial cell markers of cellular senescence at 3 months","Endothelial cell expression of p16, p21 and markers of cell senescence",{"measure":28,"description":13,"timeFrame":12},"Change from baseline in markers of cellular senescence and the senescence-associated secretory phenotype (SASP) in circulation at 3 months",{"measure":30,"description":31,"timeFrame":12},"Change from baseline in large elastic artery stiffness at 3 months","Change in aortic stiffness via carotid-femoral pulse wave velocity and\u002For carotid artery stiffness by carotid artery compliance",{"measure":33,"description":34,"timeFrame":12},"Change from baseline in cognitive function at 3 months","Change in NIH Toolbox measures of cognitive function and\u002For assessed with the Trail Making Tests from baseline to 3 months",{"allocation":36,"interventionModel":37,"interventionModelDescription":13,"primaryPurpose":38,"observationalModel":13,"timePerspective":13,"maskingInfo":39},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":40,"maskingDescription":13,"whoMasked":41},"TRIPLE",[42,43,44],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[46,51],{"label":47,"type":48,"description":13,"interventionNames":49},"Fisetin","EXPERIMENTAL",[50],"Dietary Supplement: Fisetin",{"label":52,"type":53,"description":13,"interventionNames":54},"Placebo","PLACEBO_COMPARATOR",[55],"Other: Placebo",[57,61],{"type":58,"name":47,"description":59,"armGroupLabels":60,"otherNames":13},"DIETARY_SUPPLEMENT","Fisetin will be administered in an intermittent manner with six three-day dosing periods at a dose of 2 mg\u002Fkg\u002Fday separated by two weeks.",[47],{"type":6,"name":52,"description":62,"armGroupLabels":63,"otherNames":13},"Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with six three-day dosing periods separated by two weeks.",[52],[65],{"name":66,"affiliation":5,"role":67},"Matthew J Rossman, PhD","PRINCIPAL_INVESTIGATOR",[69],{"name":70,"role":71,"phone":72,"phoneExt":13,"email":73},"Sarah Haydu","CONTACT","303-735-6410","fisetintrial@colorado.edu",[75],{"facility":76,"status":13,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":88},"University of Colorado Boulder","Boulder","Colorado","80309","United States","US",{"type":83,"coordinates":84},"Point",[85,86],-105.27055,40.01499,{"lat":86,"lon":85},[89],{"name":70,"role":71,"phone":72,"phoneExt":13,"email":73},{"type":67,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Matthew Rossman","Assistant Professor",[94],{"name":95,"class":96},"National Institute on Aging (NIA)","NIH","100659944","phase-2-fisetin-for-improving-vascular-function-in-older-adults-a-phase-ii-clinical-trial-100659944",false,"NCT07871162","Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial","Targeting Cellular Senescence With Fisetin for Improving Vascular Endothelial Function in Older Adults","Inclusion Criteria:\n\n* Age 65 years or older\n* Women must be postmenopausal\n* Body mass index (BMI) \\\u003C40 kg\u002Fm2\n* Willing to accept random assignment\n* Weight stable in the prior 2 months (\\\u003C2 kg weight change) and willing to remain weight stable throughout the study\n* Ability to understand study procedures and to comply with them for the entire length of the study\n* Absence of established, serious, unstable, chronic clinical disease (e.g., unstable CVD) that would make it unsafe for the individual to participate in the trial as determined by trial physician of record.\n\nExclusion Criteria:\n\n* Inability to refrain from alcohol for 24 hours prior to outcome assessment, alcohol dependence or abuse\n* Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with established senolytic effects) within 6 months prior to baseline testing as reported during medication review during screening. Should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the participant by the PI\n* New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)\n* Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)\n* Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing as reported during Medical History and Physical and\u002For on study screening forms\n* Inability or unwillingness of individual to give written informed consent\n* Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study\n* Blood donation within 8 weeks prior to baseline testing; unwillingness to abstain from blood donation during the study and for 8 weeks after study completion\n* Resting blood pressure \\>160 mmHg systolic or \\>100 mmHg diastolic.\n* Regular vigorous aerobic\u002Fendurance exercise (\\>6 bouts\u002Fweek at a moderate-high intensity)",true,"ALL","65 Years",{"count":108,"type":109},136,"ESTIMATED","INTERVENTIONAL",[112],"PHASE2","Aging is associated with the development of vascular dysfunction, which increases the risk for cardiovascular disease. This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults. The clinical trial will also assess if any effects of fisetin on endothelial function are associated with reduced cellular senescence. The study will also evaluate safety, tolerability and adherence with fisetin treatment.",[115,116,117],"Aging","Endothelial Dysfunction","Cellular Senescence","NOT_YET_RECRUITING","2026-10-06",{"date":121,"type":122},"2026-10-13","ACTUAL",{"date":124,"type":109},"2026-11",{"date":126,"type":109},"2031-06",{"name":5,"class":6},1]